[Helicobacter pylori infection and antimicrobial agents resistance]

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Standard seven-day triple therapies for Helicobacter pylori infection, using a proton pump inhibitor (PPI) and two antimicrobials (clarithromycin, amoxicillin, metronidazole), are increasingly failing.
• Eradication failure rates, particularly in France, approach 30%, primarily driven by growing resistance to clarithromycin (macrolides) and metronidazole (nitro-imidazoles).
• Primary clarithromycin resistance is around 10% globally (20% in France), significantly reducing eradication success. Secondary resistance contraindicates its use in second-line treatments. Amoxicillin and tetracycline resistance remain low (<2%). Metronidazole resistance is higher and impacts eradication rates, necessitating longer or alternative therapies.

Purpose of the Study:

• To address the rising challenge of Helicobacter pylori treatment failures.
• To highlight the impact of antimicrobial resistance on H. pylori eradication efficacy.
• To explore advancements in detecting H. pylori resistance.

Main Methods:

• Review of current knowledge on antimicrobial resistance patterns in H. pylori.
• Analysis of factors contributing to eradication failures.
• Discussion of emerging diagnostic methods for resistance detection.

Main Results:

• Increasing primary and secondary resistance to key antibiotics like clarithromycin and metronidazole is a major cause of H. pylori treatment failure.
• Resistance significantly reduces the effectiveness of standard triple therapies, necessitating modified or rescue regimens.
• Novel diagnostic approaches based on bacterial DNA analysis are being developed.

Conclusions:

• Understanding the genetic basis of H. pylori resistance is crucial for developing effective diagnostic tools.
• DNA-based detection methods for clarithromycin resistance have been validated.
• Future strategies will likely involve direct detection of resistance from gastric biopsies, improving personalized H. pylori treatment.